Apolipoprotein A-IV (ApoA-IV), first discovered in rat plasma in the 1970s , is a 46 kD glycoprotein with relatively high concentrations in plasma (15-37 mg/dL) . It is expressed predominantly in the mammalian small intestine (with highest expression in the duodenum), and also expressed in rodent liver at lower levels. Sensing lipid absorption in enterocytes , ApoA-IV is synthesized and packaged with lipids and other apolipoproteins into chylomicrons and secreted through the lymphatic system into the blood. Once there, as a member of exchangeable apolipoproteins, ApoA-IV dissociates from chylomicrons and transfers to HDL (high density lipoprotein) particles or circulates in lipid-free form .ApoA-IV may protect against atherosclerosis , mediate reverse cholesterol transport , act as an anti-inflammatory agent and modulate intestinal lipid absorption .
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Target-Kategorie:
Apolipoprotein A-IV/APOA4
Application Verdünnung:
Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.
Anwendungsbeschreibung:
Cross-Reactivity: Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage,it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA,5% HSA,10% FBS or 5% Trehalose),and aliquot the reconstituted protein solution to minimize free-thaw cycles., ResearchArea: Other Recombinant Protein
Recombinant Human ApolipoproteinA-IV/APOA4 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
